Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers
Open Access
- 24 November 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (23) , 8920
Abstract
The accumulation of amyloid protein aggregates in tissues is the basis for the onset of diseases known as amyloidoses. Intriguingly, many amyloidoses impact the central nervous system (CNS) and usually are devastating diseases. It is increasingly apparent that neurotoxic soluble oligomers formed by amyloidogenic proteins are the primary molecular drivers of these diseases, making them lucrative diagnostic and therapeutic targets. One promising diagnostic/therapeutic strategy has been the development of antibody fragments against amyloid oligomers. Antibody fragments, such as fragment antigen-binding (Fab), scFv (single chain variable fragments), and VHH (heavy chain variable domain or single-domain antibodies) are an alternative to full-length IgGs as diagnostics and therapeutics for a variety of diseases, mainly because of their increased tissue penetration (lower MW compared to IgG), decreased inflammatory potential (lack of Fc domain), and facile production (low structural complexity). Furthermore, through the use of in vitro-based ligand selection, it has been possible to identify antibody fragments presenting marked conformational selectivity. In this review, we summarize significant reports on antibody fragments selective for oligomers associated with prevalent CNS amyloidoses. We discuss promising results obtained using antibody fragments as both diagnostic and therapeutic agents against these diseases. In addition, the use of antibody fragments, particularly scFv and VHH, in the isolation of unique oligomeric assemblies is discussed as a strategy to unravel conformational moieties responsible for neurotoxicity. We envision that advances in this field may lead to the development of novel oligomer-selective antibody fragments with superior selectivity and, hopefully, good clinical outcomes.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/25681-3)
- Foundation for the National Institutes of Health (1RF1AG063903)
This publication has 134 references indexed in Scilit:
- In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) FragmentsAntibodies, 2013
- Cellular Aspects of Prion Replication In VitroViruses, 2013
- Prion protein at the crossroads of physiology and diseaseTrends in Neurosciences, 2012
- The intricate mechanisms of neurodegeneration in prion diseasesTrends in Molecular Medicine, 2011
- Ion mobility–mass spectrometry reveals a conformational conversion from random assembly to β-sheet in amyloid fibril formationNature Chemistry, 2010
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- An scFv Intrabody against the Nonamyloid Component of α-Synuclein Reduces Intracellular Aggregation and ToxicityJournal of Molecular Biology, 2008
- Properties, production, and applications of camelid single-domain antibody fragmentsApplied Microbiology and Biotechnology, 2007
- Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α-Synuclein that Inhibits Aggregation and Prevents α-Synuclein-induced ToxicityJournal of Molecular Biology, 2007
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature, 2002